BioSight
Companies
Replimune Group, Inc. logo

REPL

NASDAQWOBURN, MA
Replimune Group, Inc.

Replimune is a clinical-stage biotech company developing oncolytic virus therapies—specifically a platform called RPx—designed to treat cancer, potentially in combination with checkpoint inhibitor immunotherapies like anti-PD-1 drugs. The company is advancing multiple product candidates (RP1, RP2, and RP3) through clinical trials with the goal of obtaining FDA approval and commercialization.

Price history not yet available for REPL.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar